24/7 Market News Snapshot 07 May, 2025 – C4 Therapeutics, Inc. (NASDAQ:CCCC)

May 7, 2025

DENVER, Colo., 07 May, 2025 (www.247marketnews.com) – (Nasdaq:CCCC) are discussed in this article.
C4 Therapeutics, Inc. (Nasdaq:CCCC) has commenced trading today at $1.56, with shares currently at $1.605, marking an impressive rise of 13.83% from the previous close of $1.410. This substantial increase illustrates a strong bullish trend supported by active trading, with a volume of 1.54 million shares exchanged. Market analysts are closely observing key resistance levels around $1.65 and support near $1.50. A sustained rally beyond these thresholds could signify further gains, while potential pullbacks will require caution among investors.

This surge in trading comes in tandem with the announcement of significant developments within C4T’s clinical portfolio, particularly concerning cemsidomide, an investigational therapy for multiple myeloma. Recent data from the completed Phase 1 clinical trial show a compelling overall response rate (ORR) of 50% at the highest dosage of 100 μg, with notable outcomes including a minimal residual disease (MRD) negative complete response from one patient. At the 75 μg dosage, a 40% ORR was also achieved. This encouraging data has positioned C4T to initiate an expansion cohort in the coming months, emphasizing the potential for cemsidomide to become a leading treatment option for patients with multiple myeloma and non-Hodgkin’s lymphomas.

CEO Andrew Hirsch expressed optimism regarding the trial results, reinforcing C4T’s commitment to pioneering therapies through its TORPEDO platform. The company is also progressing with the ongoing Phase 1 trial of CFT8919 in collaboration with Betta Pharmaceuticals and is evaluating strategic partnerships to further its BRAF program. With total revenues reported at $7.2 million for the first quarter of 2025 and a robust cash position of $234.7 million, C4 Therapeutics is well-equipped to support its research initiatives and continue advancing treatment paradigms in oncology.

Related news for (CCCC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.